BPC
MLYS icon

Banque Pictet & Cie’s Mineralys Therapeutics MLYS Stock Holding History

Banque Pictet & Cie’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,486
Closed -$272K – 441
2025
Q4 		$272K Buy
+7,486
New +$300K ﹤0.01% 369

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Banque Pictet & Cie's MLYS Position: Q1 2026 in Review

Banque Pictet & Cie sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 7,486 shares — an estimated $272K sold.

Banque Pictet & Cie first reported a position in MLYS in Q4 2025 and held it in 1 quarter. The position peaked at $272K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Banque Pictet & Cie reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Banque Pictet & Cie sold 7,486 Mineralys Therapeutics shares in Q1 2026, an estimated $272K.
  • Banque Pictet & Cie first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 1 quarter.
  • Banque Pictet & Cie's Mineralys Therapeutics position peaked at $272K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Banque Pictet & Cie's 13F filing for Q1 2026, filed 14 Apr 2026.